At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CAI Caris Life Sciences, Inc.
Trading 02-24 14:49:44 EST
18.18
+0.54
+3.06%
High18.44Low17.15Vol1.49M
Open17.53D1 Closing17.64Amplitude7.31%
Mkt Cap5.13BTradable Cap1.67BTotal Shares282.15M
T/O26.81MT/O Rate1.62%Tradable Shares91.92M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Earning Preview: Caris Life Sciences, Inc. this quarter’s revenue is expected to increase by 0%, and institutional views are mixed
Earnings Agent  ·  02-19
Earning Preview: Caris Life Sciences, Inc. this quarter’s revenue is expected to increase by 0%, and institutional views are mixed
BRIEF-Caris Life Sciences Adds Breast Cancer Signature For Capecitabine To Ai Insights
Reuters  ·  02-24 21:31
BRIEF-Caris Life Sciences Adds Breast Cancer Signature For Capecitabine To Ai Insights
Caris launches AI signature predicting capecitabine response in HER2-negative breast cancer
Reuters  ·  02-24 21:31
Caris launches AI signature predicting capecitabine response in HER2-negative breast cancer
Caris Life Sciences Inc - Adds Breast Cancer Signature for Capecitabine to AI Insights
THOMSON REUTERS  ·  02-24 21:30
Caris Life Sciences Inc - Adds Breast Cancer Signature for Capecitabine to AI Insights
Caris Life Sciences to Participate in TD Cowen 46th Annual Health Care Conference
Reuters  ·  02-23 21:30
Caris Life Sciences to Participate in TD Cowen 46th Annual Health Care Conference
Caris Life Sciences Initiated at Outperform by Baird
Dow Jones  ·  02-17
Caris Life Sciences Initiated at Outperform by Baird
Caris Life Sciences initiated with an Outperform at Baird
TIPRANKS  ·  02-17
Caris Life Sciences initiated with an Outperform at Baird
CAI Corp Completes Connected Deals, Boosts Controlling Shareholder’s Stake
TIPRANKS  ·  02-16
CAI Corp Completes Connected Deals, Boosts Controlling Shareholder’s Stake
CAI Corp Updates Market on HK$0.14 Net Asset Value per Share
TIPRANKS  ·  02-13
CAI Corp Updates Market on HK$0.14 Net Asset Value per Share
CAI Corp Wins Strong Shareholder Backing for Equity Deals and 2026 Share Scheme
TIPRANKS  ·  02-10
CAI Corp Wins Strong Shareholder Backing for Equity Deals and 2026 Share Scheme
Caris Life Sciences Inc. to report fourth quarter and full year 2025 financial results
Reuters  ·  02-09
Caris Life Sciences Inc. to report fourth quarter and full year 2025 financial results
Press Release: AudioCodes Reports Fourth Quarter and Full Year 2025 Results and Declares Semi-Annual Dividend of 20 cents per share
Dow Jones  ·  02-03
Press Release: AudioCodes Reports Fourth Quarter and Full Year 2025 Results and Declares Semi-Annual Dividend of 20 cents per share
CAI Corp Sets Out Board Line-Up and Committee Roles
TIPRANKS  ·  02-02
CAI Corp Sets Out Board Line-Up and Committee Roles
CAI Corp Executive Director Chan Cheong Yee to Resign in February 2026
TIPRANKS  ·  01-30
CAI Corp Executive Director Chan Cheong Yee to Resign in February 2026
Caris Life Sciences Identifies Key Resistance Mechanisms to Trastuzumab Deruxtecan in Metastatic Breast Cancer
Reuters  ·  01-28
Caris Life Sciences Identifies Key Resistance Mechanisms to Trastuzumab Deruxtecan in Metastatic Breast Cancer
Caris Life Sciences' Real-World Data Uncovers Metastatic Breast Cancer Patient Responses and Resistance to Trastuzumab Deruxtecan
THOMSON REUTERS  ·  01-28
Caris Life Sciences' Real-World Data Uncovers Metastatic Breast Cancer Patient Responses and Resistance to Trastuzumab Deruxtecan
CAI Corp. to Seek Shareholder Approval for Equity Transfers, New Share Scheme
MT Newswires Live  ·  01-21
CAI Corp. to Seek Shareholder Approval for Equity Transfers, New Share Scheme
CAI Corp Calls EGM to Approve Share-Funded Acquisitions From Longling Capital
TIPRANKS  ·  01-20
CAI Corp Calls EGM to Approve Share-Funded Acquisitions From Longling Capital
CAI Corp Reports Unaudited Net Asset Value Per Share of HK$0.14 as of End-2025
TIPRANKS  ·  01-15
CAI Corp Reports Unaudited Net Asset Value Per Share of HK$0.14 as of End-2025
Could Caris Life Sciences (CAI)–Everlywell Cancer Test Tie-Up Redefine Its Precision Medicine Positioning?
Simply Wall St.  ·  01-15
Could Caris Life Sciences (CAI)–Everlywell Cancer Test Tie-Up Redefine Its Precision Medicine Positioning?

Introduction

Company Name.
Caris Life Sciences, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Caris Life Sciences, Inc. is a leading patient-centered next-generation artificial intelligence technology biology company and precision medicine pioneer. It develops and commercializes innovative solutions to transform health care through the large-scale use of comprehensive molecular information and AI/ML algorithms. Its entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology and serving the clinical, academic and biopharmaceutical markets.
Issue price:
--